I agree with all those suggestions and I'll just list a few more, if it pleases the committee.
First, at the stage of approval of medications, there should be higher standards for new products being approved. I think that currently there are too many different drugs that could potentially be abused, and in particular, too many opioids that are currently marketed in Canada.
The promotion and marketing of pharmaceuticals in Canada should be monitored proactively by Health Canada. They should not await complaints. That will of course require additional resources for Health Canada. They currently, I understand, do not have the resources to proactively monitor the marketing and promotion of medications.
Certain marketing practices should be banned.
You were quite right, Ms. Davies, when you said that there's a large challenge. Several billion dollars are spent by pharmaceutical companies in Canada every year. Estimates range from between $2 billion and $5 billion a year. It's difficult to counter that with medical education, so I think certain practices should be banned.
That would include visits from sales representatives to physicians. There is no good reason for those to take place. Samples should be banned. Sales representatives drop off samples of pharmaceuticals to physicians. Again, there is no reason for them, and in the end, patients end up paying for them.
There should never be any influence from pharmaceutical companies in the curricula of medical schools or in continuing medical education sessions. That should be completely banned and is something that the government could have a role in banning. Certainly, colleges such as the College of Family Physicians of Canada should not accredit educational sessions that are funded, sponsored, or influenced by the pharmaceutical industry.
Finally, Health Canada should also monitor for the harms, as I mentioned in my remarks. They currently don't have the resources to do that, as I understand it, but for particular medications where there is a risk of abuse, such as opioids, Health Canada should be able to say how many deaths there have been in Canada and at least provide estimates of the number of people dependent on the medications.
Finally, in order to set an example and to generate revenue for these investigations, past wrongdoings should be investigated. As I mentioned in my remarks, Purdue Pharma was investigated in the United States and ended up paying $634 million—I believe that was the amount—but nothing so far has happened in Canada. It actually sends exactly the wrong message to pharmaceutical companies in Canada. It says that it is easier here to market medications and that the regulations here are less strict.